president & CEO Gate Neurosciences - focused on tackling the challenges of developing new treatments in the area of CNS and neuropsychiatry
Jupiter, FL
Joined August 2011
- Tweets283
- Following583
- Followers258
- Likes384
Pinned Tweet
Excited to share that @GateNeuro acquired Boost Neurosciences, backed by Catalio Capital Management and based on Dr. Tom Sudhof's work, Nobel Laureate and Stanford Professor.
businesswire.com/news/home/2…
Michael G McCully retweeted
We need a lot more Dr. Jessica Steiers to pull a body of evidence together like this
@unbiasedscipod
theunbiasedscipod.substack.c…
nytimes.com/interactive/2025…
Michael G McCully retweeted
Dr. Anantha Shekhar spoke about the development of GATE-251, a positive allosteric modulator of the NMDA receptor to treat MDD in subjects with insomnia and anxiety in a Phase 2a study that demonstrated rapid efficacy which warrants further investigation.
New white paper out today! From our team at @GateNeuro describing our insights into harnessing the potential of new treatments targeting synaptic structure and function. ddw-online.com/reshaping-neu…
Michael G McCully retweeted
In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology.
They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: drugdiscoverytrends.com/gate…
Michael G McCully retweeted
Great to see coverage in @WIRED on the link between #neuroplasticity and #depression.
Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days.
#mentalhealth
A clinical trial reveals the first evidence of how the brain restructures physically in the first month on SSRIs—and the link between neuroplasticity and depression. wired.trib.al/hAlIkic
Michael G McCully retweeted
Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism
A new generation of psychedelics could offer mental-health benefits to a huge number of people.
The secret: no trips, highs, or hallucinations, @raf_ideas writes: theatlantic.com/health/archi…
Michael G McCully retweeted
Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs:
mdpi.com/1424-8247/16/11/157…
"Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!
Looking forward to presenting at CNS Summit next week in Boston!
#cnssummit2023 #neuroscience #mentalhealth #neuroplasticity #drugdevelopment #biopharma #innovation #pharma cvent.me/ArY8OB?refid=social…
Michael G McCully retweeted
🌍 Today we celebrate mental health around the world—because every mind matters. 💚 Let's foster understanding, empathy, and support for one another. 🤝 #WorldMentalHealthDay #MentalHealthMatters 🌍
TODAY IS WORLD MENTAL HEALTH DAY! Let's make #WorldMentalHealthDay top trending. Attention on social media can lead to more awareness and give #mentalhealth a higher priority worldwide. Please help us to reach as many people as possible by retweeting and using our hashtag💚
Amazing 🤯
The one and only @OzTheMentalist is blowing Wall Street minds!
See the magic with @timseymour, @guyadami, @karenfinerman and @melissaleeCNBC
Michael G McCully retweeted
.@EliLillyandCo's acquisition of @VersanisBio is a quintessential example of how a dormant, unappreciated, or non-strategic asset stalled in a pharma pipeline (in this instance from @NovartisScience) can be given new life by a dedicated management and investor team (more...)
Michael G McCully retweeted
In more than a third of patients with major depression, treatment with antidepressant drugs fails to control symptoms.
Read the full ELEKT-D trial Research Summary: nej.md/3ODZMPc
Looking forward to ASCP Annual Meeting @ASCPorg in Miami next week, where we will be presenting new data on precision medicine approaches ad translational tools #neurosciences #mentalhealth @GateNeuro
businesswire.com/news/home/2…
